Publicaciones en colaboración con investigadores/as de Institute Catalá Oncología (14)

2024

  1. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871

2022

  1. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

  2. Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors

    Neuroendocrinology, Vol. 112, Núm. 12, pp. 1155-1167

2021

  1. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

2020

  1. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    Oncologist, Vol. 25, Núm. 9, pp. 745-e1265

2019

  1. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study

    Oncologist, Vol. 24, Núm. 1, pp. 38-46

2017

  1. Optimization of RAS/BRAF mutational analysis confirms improvement in patient selection for clinical benefit to anti-EGFR treatment in metastatic colorectal cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 9, pp. 1999-2007

  2. Translational research in neuroendocrine tumors: Pitfalls and opportunities

    Oncogene, Vol. 36, Núm. 14, pp. 1899-1907

2015

  1. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 972-981

2014

  1. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014

    Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1025-1034

2013

  1. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

    European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787

  2. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial

    Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2541-2550

2008

  1. Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer

    Clinical and Translational Oncology, Vol. 10, Núm. 1, pp. 52-57

2006

  1. Polymorphisms in DNA repair genes modulate survival in cisplatin/ gemcitabine-treated non-small-cell lung cancer patients

    Annals of Oncology, Vol. 17, Núm. 4, pp. 668-675